mirogabalin mirogabalin mirogabalin (brand name tarlige; developmental code name ds-5565) is a medication developed by daiichi sankyo, a gabapentinoid. gabapentin and pregabalin are also members of this class. as a gabapentinoid, mirogabalin binds to the α2δ subunit of voltage-gated calcium channel (1 and 2), but with significantly higher potency than pregabalin. it has shown promising results in phase ii clinical trials for the treatment of diabetic peripheral neuropathic pain. mirogabalinclinical datatrade namestarligeother namesds-5565routes ofadministrationby mouthatc coden02bf03 (who) identifiers iupac name (1r,5s,6s)-6-(aminomethyl)-3-ethyl-bicyclo(3.2.0)hept-3-ene-6-acetic acid cas number1138245-13-2 ypubchem cid49802951chemspider32701007uniis7lk2kdm5ukeggd11203chemical and physical dataformulac12h19no2molar mass209.289 g·mol−13d model (jsmol)interactive image smiles ccc1=cc2c(c1)c2(cn)cc(=o)o inchi inchi=1s/c12h19no2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10h,2-3,5-7,13h2,1h3,(h,14,15)/t9-,10-,12-/m1/s1key:ftbqorvnhoiash-ckyffxlpsa-n phase iii trial results: effective: for post-herpetic neuralgia (trial: neucourse) ineffective: for fibromyalgia (trial: alday) effective: for diabetic peripheral neuropathic pain (trial: reducer) in japan, the company submitted a marketing application for treatment of peripheral neuropathic pain. the medication was approved for neuropathic pain and postherpetic neuralgia in japan in january 2019.